VItiligo RegisTry adUlts And chiLdren-France
Vitiligo
De qué trata este estudio
El registro no identifica actualmente este estudio como reclutando. Consulta su estado antes de planificar una evaluación.
- Tipo de estudio
- Observacional
- Fase
- No aplica / no indicada
- Rango de edad
- No especificado - No especificado
- Sexo admitido
- Todos los sexos
- Voluntarios sanos
- No aceptados
- Participantes
- 100 Estimado
Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.
Las explicaciones y la navegación están en español. Los textos proporcionados por el registro, incluidos títulos, resúmenes y criterios, se conservan en su idioma original. Puedes pedir orientación en español a WCR.
Acerca de la investigación
Vitiligo is a chronic skin disorder for which new therapeutic options, including topical and oral Janus kinase (JAK) inhibitors, are emerging. In this evolving therapeutic context, long-term follow-up of patients and documentation of their treatment history are important to better understand treatment outcomes and safety in routine clinical practice.
This study is a French multicenter pilot cohort conducted as a preliminary step toward the development of a national vitiligo registry. It aims to document the clinical course of patients with vitiligo, their treatments and treatment outcomes, and adverse events occurring during treatment. The study will also collect clinical, quality-of-life and patient-reported outcome data and explore potential factors associated with treatment failure or the occurrence of adverse events.
¿Quién podría participar?
La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.
Inclusion Criteria:
- Patient with a diagnosis of vitiligo, with no age restriction.
- For adult participants: the patient has provided non-opposition to participation in the study.
- For participants under 18 years of age: the holders of parental authority have provided non-opposition to the child's participation in the study.
- Patient followed in the dermatology department of a participating center.
Exclusion Criteria:
- Patient under legal protection (guardianship or curatorship).
- Any difficulty in understanding or reading French that, in the investigator's opinion, could affect the validity of questionnaire completion.
- Cognitive, mental, or psychiatric disorder that, in the investigator's opinion, prevents completion of the study protocol.
Población del estudio
Adults and children with a diagnosis of vitiligo followed in the dermatology department of one of the participating centers in France. Participants will be included regardless of age and will receive routine clinical care for vitiligo.
Entiende la evaluación inicialTratamiento, grupos y participación
El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.
- Asignación
- No informado
- Enmascaramiento
- No informado
Adults and pediatric Patients with vitiligo
Adults and children with a diagnosis of vitiligo followed in the dermatology department of a participating center. Participants receive routine clinical care for vitiligo. Clinical characteristics, current and previous treatments, treatment-related adverse events, disease severity, quality of life, and patient-reported outcomes are collected during follow-up
Other: Vitiligo treatments in routine clinical practice
Vitiligo treatments in routine clinical practice OTHER
Participants receive vitiligo treatments as part of routine clinical care. No treatment is assigned by the study protocol. Current and previous vitiligo treatments, including combination therapies, are documented during follow-up, together with clinical outcomes and treatment-related adverse events.
Qué evalúan los investigadores
Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.
Medidas principales
Clinical course of vitiligo under treatment assessed by T-VASI
Plazo: Baseline, 6 months, 1 year, and 2 years
Clinical course and disease severity in patients receiving currently used treatments for vitiligo, including combination therapies, will be assessed using the Total Vitiligo Area Severity Index (T-VASI). This assessment will be used to monitor changes in vitiligo severity during treatment
Clinical course of vitiligo under treatment assessed by sIGA
Plazo: Baseline, 6 months, 1 year, and 2 years
Clinical course and disease severity in patients receiving currently used treatments for vitiligo, including combination therapies, will be assessed using the Investigator Global Assessment (sIGA). This assessment will be used to monitor changes in vitiligo severity during treatment
Medidas secundarias
Descriptive data of BMI
Plazo: Baseline
Descriptive data of BMI will be done using mean and median.
Treatment-related adverse events
Plazo: Baseline, 6 months, 1 year, and 2 years
Adverse events occurring in patients receiving currently used treatments for vitiligo, including combination therapies.
Measure of the quality of life
Plazo: Baseline, 1 year, and 2 years
EQ-5D for adults participants.
Vitiligo burden
Plazo: Baseline, 6 months, 1 year, and 2 years
Vitiligo burden will be assessed using the Vitiligo Impact Patient scale (VIPs).
Change in vitiligo disease activity assessed by the Vitiligo Signs of Activity Score (VSAS)
Plazo: Baseline, 6 months, 1 year, and 2 years
Vitiligo disease activity will be assessed using the Vitiligo Signs of Activity Score (VSAS). Changes in VSAS scores will be monitored over time to evaluate disease activity during follow-up.
Patient Self-reported Vitiligo extent (SA-VES)
Plazo: Baseline, 6 months, 1 year, and 2 years
Patients self-reported of disease extent will be assessed by the Self-Assessment Vitiligo Extent Score (SA-VES).This assessment will be used to monitor changes in the extent of vitiligo over time
Feasibility of the multicenter vitiligo registry
Plazo: Through study completion, up to 5 years
Number of participants enrolled, missing data, and participants lost to follow-up.
Measure of the quality of life
Plazo: Baseline, 1 year, and 2 years
Child DLQI for pediatric participants.
Age of participants at enrollment
Plazo: Baseline
Age of participants at enrollment will be recorded in years and summarized using descriptive statistics.
Distribution of participants by sex
Plazo: Baseline
The number and percentage of participants in each recorded sex category will be reported.
Number of participants with comorbidities
Plazo: Baseline, 1 year, and 2 years
The number and percentage of participants with at least one recorded comorbidity will be reported.
Number of participants with previous treatments for vitiligo
Plazo: Baseline
The number and percentage of participants who received treatment for vitiligo prior to enrollment will be reported.
Number of participants with a history of cancer
Plazo: Baseline, 1 year, and 2 years
The number and percentage of participants with a recorded diagnosis of cancer, including skin cancer, will be reported.
F-VASI - Facial extent of vitiligo
Plazo: Baseline, 6 months, 1 year, and 2 years
Facial vitiligo severity will be assessed using the Facial Vitiligo Area Severity Index (F-VASI). This assessment will be used to monitor changes in facial vitiligo severity over time
VNS - Patient reported Vitiligo noticeability scale (VNS)
Plazo: Baseline, 6 months, 1 year, and 2 years
Vitiligo noticeability will be assessed using the Vitiligo Noticeability Scale (VNS). This assessment will be used to monitor changes in the perceived noticeability of vitiligo over time
PHQ-4 - Patient Health Questionnaire to measure Psychological distress
Plazo: Baseline, 6 months, 1 year, and 2 years
Psychological distress will be assessed using the Patient Health Questionnaire-4 (PHQ-4). Changes in PHQ-4 scores will be monitored over time to evaluate psychological distress during follow-up
GAD-7 - Anxiety assessment
Plazo: Baseline, 6 months, 1 year, and 2 years
Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 (GAD-7). Changes in GAD-7 scores will be monitored over time to evaluate anxiety symptoms during follow-up
PUSH-D - Stigma linked to vitiligo
Plazo: Baseline, 6 months, 1 year, and 2 years
Perceived and enacted stigma of vitiligo changes will be assessed using the PUSH-D questionnaire. Changes in PUSH-D scores will be monitored over time during follow-up
Revisa las tablas completas y sus limitaciones en el registro oficial.
Abrir resultados oficiales ↗Centros de investigación (1)
El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.
1 centros
Assistance Publique Hôpitaux de ParisCréteil, FranceEstado desconocido
Equipo y fechas
- Patrocinador principal
- Assistance Publique - Hôpitaux de Paris
- Inicio del estudio
- 2026-11 Estimado
- Finalización primaria
- 2031-11 Estimado
- Finalización del estudio
- 2031-11 Estimado
- Primera publicación
- 10 nov 2026 Real
- Última actualización
- 10 nov 2026 Real
Contactos oficiales del estudio
Título oficial del estudio
VItiligo RegisTry adUlts And chiLdren-France
Consulta a Wellness Clinical Research
Tu mensaje va a WCR, incluso si otra organización realiza este estudio. WCR puede orientarte, pero podría no realizar este estudio, tener acceso a su equipo ni poder inscribirte.
Fuente: API v2 de ClinicalTrials.gov. Patrocinadores e investigadores envían la información. La NLM no aprueba la seguridad ni la ciencia de todos los estudios registrados. Aviso del registro.
Consultado: 12 nov 2026 · Última actualización del registro: 10 nov 2026